This Science News Wire page contains a press release issued by an organization and is provided to you "as is" with little or no review from Science X staff.

HNP-1 reverses hypertensive left ventricular hypertrophy by inhibiting the NF-кB signaling pathway

September 15th, 2023
HNP-1 reverses hypertensive left ventricular hypertrophy by inhibiting the NF-кB signaling pathway
Blood Pressure, Left Ventricular Hypertrophy Indexes, and HNP-1 Level in the Two Groups. *P < 0.05, **P < 0.01, ***P < 0.001. SBP, systolic blood pressure; DBP, diastolic blood pressure; 24 h SBP, 24 h systolic blood pressure; 24 h DBP, 24 h diastolic blood pressure; D SBP, daytime systolic blood pressure; D DBP, daytime diastolic blood pressure; N SBP, night systolic blood pressure; N DBP, night diastolic blood pressure; PP, pulse pressure; LEVDd, left ventricular end diastolic dimension; IVST, interventricular septal thickness; LVPWT, left ventricular posterior wall thickness; LVM, left ventricular mass; LVMI, left ventricular mass index; LVEF, left ventricle ejection fraction; HNP-1, human neutrophil peptide-1. Credit: Cardiovascular Innovations and Applications (2023). DOI: 10.15212/CVIA.2023.0057

Human neutrophil peptide-1 (HNP-1) is a commonly investigated therapeutic agent. However, its role in hypertensive left ventricular hypertrophy (HLVH) remains unclear.

In a new study published in Cardiovascular Innovations and Applications, HNP-1 levels were measured in patients with hypertension and treated HLVH rat and H9c2 cell hypertrophy models with HNP-1. Cardiomyocyte hypertrophy indexes (i.e., single-cell surface area, left ventricular fibrosis area, BNP levels, and β-MHC levels) were measured with hematoxylin-eosin and Masson's trichrome staining and WB. NF-кB signaling factors (i.e., IKKβ, p-IKKβ, IкBα, p-IкBα, p65, and p-p65) were measured with WB and qPCR. Finally, inflammatory factors (i.e., IL-6, IL-1α, and TNF-α) were measured with ELISA.

HNP-1 levels were lower in the exposure than the control groups (M (95% CI), 48.83 (45.64–52.26) vs. 59.03 (55.62–62.54), P = 0.000). Diminished HNP-1 was associated with HLVH occurrence in patients. HLVH rat and H9c2 cell hypertrophy models revealed elevated cardiomyocyte hypertrophy indexes and NF-кB signaling and inflammatory factors. However, each HNP-1 treatment group showed lower levels of the aforementioned indices than were observed in the model groups.

Diminished HNP-1 is a risk factor for HLVH. HNP-1 treatment may reverse HLVH by inhibiting NF-кB signaling pathways.

More information:
Xiaorong Duan et al, HNP-1 Reverses Hypertensive Left Ventricular Hypertrophy by Inhibiting the NF-кB Signaling Pathway, Cardiovascular Innovations and Applications (2023). DOI: 10.15212/CVIA.2023.0057

Provided by Compuscript Ltd

Citation: HNP-1 reverses hypertensive left ventricular hypertrophy by inhibiting the NF-кB signaling pathway (2023, September 15) retrieved 28 November 2024 from https://sciencex.com/wire-news/456243169/hnp-1-reverses-hypertensive-left-ventricular-hypertrophy-by-inhi.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
Back to list